How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.
Blood Cancer Discov
; 2(6): 562-567, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1518191
ABSTRACT
Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19
Topics:
Vaccines
Limits:
Adult
/
Humans
Language:
English
Journal:
Blood Cancer Discov
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS